When the math doesn’t add up 📊

This setup has a BIG GAP in valuation

August 29, 2025

A big mismatch has formed. When I saw a similar setup in March, we got a 40%+ move. Take a close look at this one before the market opens.

TODAY’S TOP ALERT! 

Citius Pharma (Nasdaq: CTXR)

👉  CTXR is TODAY’S #1 ALERT 👈

Happy Friday, Folks!

My “tactical trade” idea from yesterday reached an intraday high of 18%, following Wednesday’s idea, which surged 14% that day.

Sometimes, these are very fast moving ideas… so have your gameplan in place and stick to it!

Now, I’m taking aim one more time before I pack it up for the weekend…

Today’s “tactical” idea is a stock that ran up 40%+ the day I alerted it in March and was one of the top 10 movers in the entire market.

It ripped 264% from June into early July. When I last alerted it, on July 3, it peaked at an 18% gain that day.

Go ahead and pull up Citius Pharmaceuticals Inc (CTXR) right now.

The company raised capital over June and July, which pulled it down from its intra-month peaks, but an interesting setup has formed, which you should keep on your radar right away.

Here is the really interesting part of the story to me…

For background, CTXR is an 84% owner of Citius Oncology (CTOR), which the company created last year to advance its lead asset, LYMPHIR, to the commercial stage.

Yahoo! Finance lists CTOR’s market cap at $166 million, indicating that CTXR’s 84% equity stake is currently worth approximately $139 million.

There’s a huge mismatch given that CTXR’s market cap is listed as approximately $24 million.

At the same time, CTOR has jumped 31% over the past week while CTXR has gained just 14%.

Back in March, it was a similar ramp-up in CTOR that clued me in to the imminent CTXR spike, and we’re seeing similar things right now.

That’s why I think today could be a big one for CTXR. Dial in to see how this one plays out!

👉  CTXR is TODAY’S #1 ALERT 👈

CTXR itself is a late-stage biopharmaceutical company with a diversified pipeline and several near-term catalysts.

The New Jersey-based company is set to completely transform the standard of care in patients with infections stemming from Central Venous Catheters (CVCs).

If its lead candidate, Mino-Lok, is approved — and that’s looking increasingly likely — it would be the first and only FDA-approved antibiotic lock solution for salvaging CVCs.

That may not sound like the most exciting thing, but it would actually be a really huge deal.

For those who don’t know, CVCs are thin tubes that are inserted into large veins in the chest, neck, or groin.

They’re used to provide patients with medications, fluids, and nutrition and for regular blood sampling.

Every year, 7 million CVCs are used in the U.S., and 4 million of those are long-term, meaning they get used longer than a month.

Each year, approximately 500,000 of these catheters get infected, resulting in conditions known as central line-associated bloodstream infection (CLABSI) and catheter-related bloodstream infection (CRBSI).

The standard “cure” for CLABSI/CRBSI is for the patient to take a round of antibiotics and have the CVC removed and replaced.

The problem is it is extremely painful and even traumatizing to remove/replace a CVC, and it can interrupt care for the patient’s underlying condition…

(Many of these patients are extremely vulnerable — undergoing chemotherapy, ICU patients, etc.)

One study found that 57%–67% of patients had adverse physical and psychological symptoms from CVC removal and replacement, with 32% experiencing moderate-to-severe symptoms.

It’s also very expensive — costing about $10,000 — and the overall CLABSI/CRBSI treatment can cost as much as $65,000.

CTXR is hoping to replace this unacceptable standard of care with Mino-Lok, an antibiotic solution intended to actually salvage infected catheters.

Mino-Lok has gone through a complete Phase 3 trial, and the company reported topline results in May last year, noting that it had achieved the primary endpoint and several secondary endpoints with very high statistical significance.

Citius CEO Leonard Mazur said the CTXR was “extremely pleased by the strong results,” and the company held a Type C meeting with the FDA in November that provided CTXR with “clear, constructive, and actionable guidance.”

The company estimates the potential market for Mino-Lok at more than $1 billion in the U.S. and $2 billion globally.

CTXR spun off of a different lead asset, LYMPHIR, into a wholly owned subsidiary named Citius Oncology, and that subsidiary merged with a SPAC last August.

As mentioned, CTXR now holds approximately 84% of the combined company, which operates as Citius Oncology, Inc. (CTOR).

A few days prior to the merger, LYMPHIR was approved by the FDA for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).

CTCL is a rare form of non-Hodgkin lymphoma that afflicts roughly 3,000 new people each year, and the overall market for it is estimated at $400 million. 

I don’t need to tell you what a huge deal FDA approval is, and CTXR said this month that it expects LYMPHIR to launch in Q4 2025.

CTXR’s third major “shot on goal” is Halo-Lido, “a proprietary topical formulation … that is intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids.”

Halo-Lido had a very positive Phase 2b trial, and Citius is now planning on an end of phase II meeting with the FDA to discuss the next steps in the regulatory and clinical development program.

If all goes well, Halo-Lido would be the first FDA-approved prescription product to treat hemorrhoids.

Citius insiders show strong faith in the company, with co-founder and CEO Leonard Mazur investing $22.5 million of his own money directly into the company, and with co-founder and Executive Vice Chairman Myron Holubiak investing $4 million.

I love companies where management has that type of “skin in the game.” 

Analysts are bullish too: 

  • D. Boral Capital placed to a $6 12-month price target on June 10

  • H.C. Wainwright reiterated a BUY with a whopping $4 price target on April 14

Those price targets represent potential upsides between 328% and 185% based on yesterday’s closing price.

As you do your own research, be sure to review this investor presentation from March as well as the company website.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: CTXR has a strong pipeline that included its first-ever FDA approval last year. MINO-Lok and Halo-Lido could also transform the standards of care for their indications.

With CTOR (an 84%-owned subsidiary of CTXR) shares up over 30% over the past week, and CTXR up “just” 14%, I’m watching to see if CTXR catches up today.

Stay locked in to CTXR today to watch all the fireworks! 🎇

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on August 29, 2025. Additionally, we received fifteen thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on July 3, 2025. Before this, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on March 31, 2025, and we also received fifteen thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on February 19, 2025.  Before that, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on September 23, 2024, and we also received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on July 11, 2024 as well as fifteen thousand dollars via ach bank transfer by Lifewater Media for advertising Citius Pharmaceuticals for a one marketing program on March 9th, 2023.. It might seem obvious, but while our client claims not to own any shares in Citius Pharmaceuticals, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Citius Pharmaceuticals might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.